Germany-based Hyglos and scientists from the universities of Tübingen, Münster and Munich join forces to develop a phage-based active substance against the dreaded hospital pathogen Staphylococcus aureus.
Their secret lies in a highly effective protein from bacteria-specific viruses, the so-called bacteriophages, capable of rapidly killing the bacteria, which frequently occur in the nose. Due to the specific action of this protein, the natural microflora is maintained. This prophylactic treatment could counteract the spread of methicillin-resistant staphylococcus aureus (MRSA) in hospitals and, thereby, prevent patients from infections.
“We do like to describe it as a MRSA-killing protein, even if it sounds somewhat sensational” explains Dr. Wolfgang Mutter from Hyglos GmbH.
According to experts, one person in three carries the bacterium Staphylococcus aureus in their nose. It is not dangerous in the case of healthy individuals, but can quickly become a problem if the carrier is admitted to a hospital. The pathogen can then insert inself into wounds and potentially cause dangerous infections,